scholarly journals OBJECTS OF INTELLECTUAL PROPERTY IN N. N. BLOKHIN NATIONAL MEDICAL RESEARCH CENTER OF ONCOLOGY CREATED IN 2019–2020

2021 ◽  
Vol 20 (1) ◽  
pp. 80-83
Author(s):  
О. I. Tarasova ◽  
A. A. Ryzhova ◽  
М. I. Savinova ◽  
V. D. Borodin

The results of the intellectual activity of the researchers of the N. N. Blokhin National Medical Research Center  of Oncology of the Ministry of Health of the Russia in 2019–2020 are presented in the short message. It is high‑ lighted that the number of patents is an index of an innovative level in the organization. 

2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Anna Lantsova ◽  
Irina Golubeva ◽  
Larisa Borisova ◽  
Lyudmila Nikolaeva ◽  
Lydia Ektova ◽  
...  

Abstract Objective The current scientific research direction is development of drugs with a targeted effect on malignant tumors. One of the promising groups is indolocarbazoles and their derivatives, which can initiate various tumor cell death pathways. Russian scientists from N. N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russian Federation has developed a new experimental drug form of the original compound LCS 1269 with cytotoxic and antiangiogenic properties, blocking vasculogenic mimicry in tumor. The study aim is the experimental drug form LCS 1269 antitumor activity on models of transplantable mouse tumors B-16 melanoma and Lewis epidermoid lung carcinoma (LLC) with different routes and modes of administration. Material and methods Female F1 hybrid mice (C57Bl/6 x DBA/2) and male and female linear mice C57BL/6 were used for management of tumor strains. Mice were obtained from N. N. Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russian Federation vivarium. The antitumor effect was assessed by tumor growth inhibition (TGI) and increase of treated animal’s life span (ILS) compared to the control. Results The experimental drug form showed high antitumor activity when administered intravenously once at doses of 100 and 120 mg/kg (TGI = 98–82% and TGI = 95–77%, respectively, ILS = 24%, p < 0.05) on melanoma B-16 mice. On LLC mice, the experimental drug form showed that the intravenous administration route was effective in the range of doses from 60 to 80 mg/kg with a 5 day administration regimen with an interval of 24 h. A dose of 70 mg/kg had maximum effect at the level of TGI = 96–77% (p < 0.05) with its retention for 20 days after the end of treatment. Conclusion The studies have shown that the new compound LCS 1269 in the original drug form, has a pronounced antitumor activity and significantly reduces the volume of tumor mass both on melanoma B-16 and on LLC. It allows us to recommend continue the search for sensitivity of animal transplantable tumors to LCS 1269.


Author(s):  
Igor Anatolevich Doroshev ◽  
Ivan Sokratovich Stilidi ◽  
Zhanna Aleksandrovna Zavolskaia ◽  
Denis Anatolevich Riabchikov ◽  
Vadim Maratovich Kulushev ◽  
...  

The article provides an example of a successful optimization of the work in a research and advisory department of N.N. Blokhin National Medical Research Center of Oncology Ministry of Health of Russia. All stages of this process are described in detail – from creating a project office and identifying problems to implementing methods for solving them and evaluating results. This work resulted in improving of the quality of medical care provided to the population, which is the most important task of any medical institution. In addition, this optimization experience may be useful for the implementation of similar activities in other health facilities in Russia.


2018 ◽  
Vol 17 (3) ◽  
pp. 89
Author(s):  
O. I. Tarasova ◽  
A. A. Ryzhovа ◽  
I. Yu. Kubasovа ◽  
N. V. Golubtsova ◽  
L. Yu. Grivtsova

.


Author(s):  
D. Yu. Yurchenko ◽  
S. A. Kuznetsov ◽  
Yu. Yu. Kozel ◽  
E. M. Frantsiyants ◽  
G. A. Mkrtchyan ◽  
...  

Relevance. One of the leading positions among malignant tumors of the musculoskeletal system in children and adolescents has recently begun to be occupied by Ewing’s sarcoma (ES). The prognosis of patients suffering from this onconosology remains extremely unfavorable even in the absence of distant metastases and timely initiation of antitumor treatment. The authors present 10 years of experience in the management of pediatric and adolescent patients with ES in the pediatric oncology department of the National Medical Research Center of Oncology, Ministry of Health of Russia.Materials and methods. The study included pediatric and adolescent patients diagnosed with ES of I—IV stages of various localizations, who were treated in the Pediatric Oncology Department of the National Medical Research Center of Oncology, Ministry of Health of Russia in the period from 2009 to 2019. We analyzed 2- and 5-year overall (OS) and event-free (EFS) survival in patients who received combined and complex antitumor treatment for various forms of tumor dissemination according to the EURO-EWING 2008protocol, which included neo-and adjuvant polychemotherapy, including high-dose, radical surgical treatment, and also radiation therapy.Results. The median 5-year OS and EFS in the general group of the studied formulations was 60 and 17 months, respectively. The indicators of 2- and 5-year OS and EFS in patients of the general group were 80.6 % and 56.7 %, 38.6 % and 10.6 %, respectively. The volume of the performed antitumor treatment, as well as the form of the advanced tumor process, did not have a significant effect on OS and EFS indicators (p > 0.05). At the same time, the chances of developing ES in boys were statistically significantly higher by 2.2 times in comparison with girls (95 % confidence interval 1.1—4.3).Conclusion. The obtained OS and EFS indices indicate unsatisfactory results of anticancer therapy and extremely high aggressiveness of the biological behavior of the tumor, regardless of the form of spread of the tumor process.


Author(s):  
Yu. S. Paskhalova

The article presents a brief biography of the senior researcher in wounds and wound infections department and clinical microbiologist of the Federal State Budgetary Institution “A. V. Vishnevsky National Medical Research Center of Surgery” Ministry of Health of Russia Leonid Aleksandrovich Blatun (03/29/1941) in honor of his 80th anniversary, of which 55 years passed within the walls of the A. V. Vishnevsky institute of surgery!


2021 ◽  
Vol 1 (3) ◽  
pp. 132-133
Author(s):  
Kh. A. Tengizov ◽  
S. V. Shahidzhanova ◽  
M. A. Saidova

This paper describes the experience of teaching transthoracic echocardiography (TTE) skills on simulation equipment, accumulated over 2 years of training of residents in the direction of "Cardiology" at the Federal State Budgetary Institution "National Medical Research Center of Cardiology" of the Ministry of Health of the Russian Federation (Cardiocenter).


Author(s):  
Yu. S. Paskhalova

The article presents a brief biography of the permanent head of the anesthesiology and resuscitation group in wounds and wound infections department of the Federal State Budgetary Institution “A. V. Vishnevsky National Medical Research Center of Surgery” Ministry of Health of Russia Alfred A. Zvyagin (05/22/1940) in honor of his 80th anniversary, of which 52 years passed within the walls of the A. V. Vishnevsky institute of surgery!


Sign in / Sign up

Export Citation Format

Share Document